US equities
|
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MSFT
$530.14
▼-0.16%
MU
$934.27
▼-4.98%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
GOOGL
$283.82
▼-12.64%
GOOG
$282.32
▼-12.29%
MSFT
$530.14
▼-0.16%
MU
$934.27
▼-4.98%
AMZN
$243.79
▼-4.25%
META
$624.52
▲+1.96%
NVDA
$213.66
▼-0.80%
AAPL
$348.91
▲+1.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
9.560
-5.250 (-35.45%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
August 06, 2026
Via
Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Beats Q2 Estimates on Record Revenue, Shares Jump
↗
August 06, 2026
Via
Chartmill
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
August 06, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026
July 30, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 17, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen
↗
June 29, 2026
Via
Chartmill
Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market
↗
May 07, 2026
Via
Chartmill
This Stock Is Up 74% This Year: Is It Too Late to Buy?
↗
July 08, 2026
The biotech is clearly innovative, but sometimes that's not enough.
Via
The Motley Fool
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
July 04, 2026
Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.
Via
The Motley Fool
Topics
Artificial Intelligence
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 23, 2026
Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.
Via
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
June 19, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
June 08, 2026
From
Biotech Insider
Via
GlobeNewswire
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
June 03, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Stock Has Been Hammered. Is This the Buying Opportunity Aggressive Investors Have Been Waiting For?
↗
June 02, 2026
Tread carefully, but certain factors make this speculative biotech play stand out.
Via
The Motley Fool
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies
June 01, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
Via
Investor Brand Network
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
June 01, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
June 01, 2026
From
BioMedWire
Via
GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 22, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present at Upcoming Conference
May 21, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance (IOVA) Q1 2026 Earnings Transcript
↗
May 08, 2026
Iovance (IOVA) Q1 2026 Earnings Transcript
Via
The Motley Fool
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
May 07, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
This Beaten-Down Growth Stock Could Soar 165%, According to Wall Street
↗
May 02, 2026
It could just as well drop by 50% -- or more -- over the next 12 months.
Via
The Motley Fool
Topics
Death
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
April 27, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?
↗
April 10, 2026
This oncology specialist has proven innovative abilities.
Via
The Motley Fool
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 20, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
↗
March 12, 2026
Via
MarketBeat
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036
↗
March 05, 2026
If you decide to invest in this company, it's probably best to start small.
Via
The Motley Fool
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead?
↗
March 05, 2026
Investors are increasingly comparing ImmunityBio and Iovance Biotherapeutics as both cancer drug developers move into catalyst-heavy phases.
Via
Stocktwits
Iovance Biotherapeutics to Present at Upcoming Conferences
February 26, 2026
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
24
25
Next >
